Lévy Emmanuel, Agbokou Catherine, Ferreri Florian, Chouinard Guy, Margolese Howard C
Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
Can J Clin Pharmacol. 2007 Summer;14(2):e234-9. Epub 2007 Jun 12.
Atypical antipsychotics have been associated with weight gain. This study examines the efficacy of adjunctive topiramate in patients with schizophrenia and schizoaffective disorder with antipsychotic-induced weight gain.
A 2-year retrospective case analysis was performed in all 300 patients of the outpatient Special Follow-up Clinic for chronic schizophrenia and related psychoses at the Allan Memorial Institute, McGill University Health Centre (Montreal, Canada), a tertiary care University teaching hospital.
10 patients met study inclusion criteria. Mean daily topiramate dose was 197.5 mg (A+/-77) (range, 125-400 mg). Topiramate produced continued weight loss throughout the study duration without tolerance. Patients treated for 6 months and more had significantly higher Body Mass Index (BMI) differences than those treated for shorter durations (BMI-d6 months=-4.7A+/-2.4; BMI-d2 months=-3.2A+/-2.3; P=0.015). BMI changes were similar across genders.
This study supports topiramate use to target weight loss in stable overweight schizophrenic patients as a potential therapy that requires further investigation.
非典型抗精神病药物与体重增加有关。本研究探讨辅助使用托吡酯对患有精神分裂症和分裂情感性障碍且因抗精神病药物导致体重增加的患者的疗效。
在加拿大蒙特利尔麦吉尔大学健康中心艾伦纪念研究所的慢性精神分裂症及相关精神病门诊特殊随访诊所的所有300例患者中进行了一项为期2年的回顾性病例分析，该研究所是一家三级护理大学教学医院。
10例患者符合研究纳入标准。托吡酯的平均日剂量为197.5毫克（平均值±77）（范围为125 - 400毫克）。在整个研究期间，托吡酯持续导致体重减轻且无耐受性。治疗6个月及以上的患者的体重指数（BMI）差异显著高于治疗时间较短的患者（治疗6个月时BMI差值 = -4.7±2.4；治疗2个月时BMI差值 = -3.2±2.3；P = 0.015）。不同性别的BMI变化相似。
本研究支持将托吡酯用于稳定的超重精神分裂症患者以减轻体重，这是一种需要进一步研究的潜在治疗方法。
